Q4 EPS Forecast for Tenax Therapeutics Raised by Analyst

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities research analysts at Leerink Partnrs increased their Q4 2025 earnings per share (EPS) estimates for Tenax Therapeutics in a research report issued to clients and investors on Wednesday, November 12th. Leerink Partnrs analyst D. Risinger now forecasts that the specialty pharmaceutical company will earn ($3.83) per share for the quarter, up from their prior forecast of ($5.53). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ FY2026 earnings at ($6.50) EPS, FY2027 earnings at ($5.55) EPS, FY2028 earnings at ($3.83) EPS and FY2029 earnings at ($2.08) EPS.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Wednesday, November 12th. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.93.

A number of other analysts have also recently weighed in on the stock. Guggenheim cut their price objective on shares of Tenax Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, August 14th. Piper Sandler initiated coverage on shares of Tenax Therapeutics in a research note on Monday, September 8th. They set an “overweight” rating and a $20.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenax Therapeutics in a research report on Tuesday, November 11th. Finally, Wall Street Zen upgraded shares of Tenax Therapeutics to a “sell” rating in a research note on Saturday, October 25th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Tenax Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Price Performance

NASDAQ TENX opened at $7.10 on Monday. The company has a market cap of $32.40 million, a P/E ratio of -7.72 and a beta of 1.52. The stock has a 50-day moving average of $6.99 and a two-hundred day moving average of $6.30. Tenax Therapeutics has a 1-year low of $4.63 and a 1-year high of $8.24.

Institutional Investors Weigh In On Tenax Therapeutics

A hedge fund recently bought a new stake in Tenax Therapeutics stock. Virtu Financial LLC bought a new position in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 12,119 shares of the specialty pharmaceutical company’s stock, valued at approximately $92,000. Virtu Financial LLC owned 0.27% of Tenax Therapeutics as of its most recent SEC filing. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.